Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BTAI
stocks logo

BTAI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
166.00K
-54.64%
-0.850
-76.19%
366.00K
+117.86%
-1.370
-8.67%
399.33K
+232.78%
-1.147
-53.2%
Estimates Revision
The market is revising Downward the revenue expectations for BioXcel Therapeutics, Inc. (BTAI) for FY2025, with the revenue forecasts being adjusted by -24.68% over the past three months. During the same period, the stock price has changed by -44.85%.
Revenue Estimates for FY2025
Revise Downward
down Image
-24.68%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-7.48%
In Past 3 Month
Stock Price
Go Down
down Image
-44.85%
In Past 3 Month
Wall Street analysts forecast BTAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BTAI is 10.67 USD with a low forecast of 4.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast BTAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BTAI is 10.67 USD with a low forecast of 4.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
1 Sell
Hold
Current: 2.090
sliders
Low
4.00
Averages
10.67
High
18.00
Current: 2.090
sliders
Low
4.00
Averages
10.67
High
18.00
Mizuho
Neutral
maintain
$2 -> $4
2025-09-12
Reason
Mizuho
Price Target
$2 -> $4
2025-09-12
maintain
Neutral
Reason
Mizuho raised the firm's price target on BioXcel Therapeutics to $4 from $2 and keeps a Neutral rating on the shares. The firm cites the positive Phase 3 SERENITY At-Home study data for BXCL501 for the target doubling. Mizuho's risk-adjusted sales estimate for Igalmi in peak year 2037 is now projected at $390M across three indications, from $325M prior. However, the firm sees continued uncertainty around what type of financing BioXcel will undertake to provide more financial stability.
H.C. Wainwright
Raghuram Selvaraju
Buy
maintain
$8 -> $10
2025-08-15
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$8 -> $10
2025-08-15
maintain
Buy
Reason
H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on BioXcel Therapeutics to $10 from $8 and keeps a Buy rating on the shares following the Q2 report. The firm cites "heightened enthusiasm" for BXCL501's prospects for the target increase. The analyst views the SERENITY readout as low-risk and believes BioXcel could file for the expanded label of BXCL501 by the end of this year and may receive the label extension in the back half of 2026.
Lucid Capital
Lucid Capital
Buy
maintain
$15
2025-07-15
Reason
Lucid Capital
Lucid Capital
Price Target
$15
2025-07-15
maintain
Buy
Reason
Lucid Capital reiterates a Buy rating on BioXcel Therapeutics with a $15 price target after the company announced that the U.S. Patent and Trademark Office approved its patent application which covers the use of a single dose of dexmedetomidine in an oromucosal formulation for treating acute agitation in schizophrenia or bipolar patients with QT prolongation under six microseconds. Once officially granted, the patent will be eligible for inclusion in the FDA's Orange Book as the 14th listed patent for Igalmi and is expected to expire on January 12, 2043, pending any patent term adjustments, the analyst tells investors in a research note.
Lucid Capital
NULL
to
Buy
initiated
$66
2025-06-25
Reason
Lucid Capital
Price Target
$66
2025-06-25
initiated
NULL
to
Buy
Reason
Lucid Capital initiated coverage of BioXcel Therapeutics with a Buy rating and $66 price target. BioXCel is expanding the use of its approved agitation drug, Igalmi, for at-home use and for Alzheimer's disease, the analyst tells investors in a research note. The firm says there are 7M patients diagnosed with Alzheimer's disease in the U.S. alone and the numbers are expected to double every 20 years with the aging population. It sees blockbuster potential for Igalmi.
H.C. Wainwright
H.C. Wainwright
maintain
$3 -> $8
2025-06-23
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$3 -> $8
2025-06-23
maintain
Reason
H.C. Wainwright raised the firm's price target on BioXcel Therapeutics to $8 from $3 and keeps a Buy rating on the shares. The firm cites After the dilution associated with the most recent equity financing in March as well as the impact of the reverse stock split implemented in February for the new target.
Rodman & Renshaw
Elemer Piros
Strong Buy
Initiates
$65
2025-03-19
Reason
Rodman & Renshaw
Elemer Piros
Price Target
$65
2025-03-19
Initiates
Strong Buy
Reason
Rodman & Renshaw initiated coverage of BioXcel Therapeutics with a Buy rating and $65 price target. The firm sees e blockbuster potential and over 2,900% share upside with BioXCel expanding the use of its approved drug, Igalmi, for at-home use and for Alzheimer's disease. The convenience of using the drug at home grows the potential by tenfold, with a market potential of $2B in the U.S., the firm tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for BioXcel Therapeutics Inc (BTAI.O) is -0.50, compared to its 5-year average forward P/E of -2.92. For a more detailed relative valuation and DCF analysis to assess BioXcel Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.92
Current PE
-0.50
Overvalued PE
0.09
Undervalued PE
-5.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.59
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.31
Undervalued EV/EBITDA
-4.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
72.57
Current PS
0.00
Overvalued PS
199.75
Undervalued PS
-54.61
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

BTAI News & Events

Events Timeline

(ET)
2025-11-21
10:22:49
FDA Approves BioXcel Therapeutics' Igalmi Supplement for New Use
select
link
2025-11-12 (ET)
2025-11-12
07:12:35
BioXcel Therapeutics Announces Q3 Earnings Per Share of $2.18, Exceeding Consensus Estimate of $1.34
select
2025-10-14 (ET)
2025-10-14
07:04:45
BioXcel Reveals Findings from Correlation Study of SERENITY At-Home Trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
12-03Globenewswire
BioXcel Therapeutics Hosts Virtual Roundtable on Self-Administered Treatment Opportunities
  • New Patient Care Perspective: BioXcel Therapeutics is set to host a virtual roundtable on December 8, focusing on the 57 to 77 million annual episodes of acute agitation associated with bipolar disorder and schizophrenia in the U.S., aiming to explore safe and effective self-administered treatment options at home to enhance patient care quality.
  • Strong Expert Lineup: The event will feature leading medical experts, including Dr. Leslie Citrome, Clinical Professor of Psychiatry at New York Medical College, who will discuss shifts in treatment paradigms and future innovations, aiding clinicians and caregivers in better addressing patient needs.
  • Industry-Wide Impact: With growing attention on the potential for home self-treatment, this roundtable not only provides crucial insights for investors and healthcare professionals but may also catalyze transformative changes in the acute mental health care sector.
  • Interactive Engagement Opportunity: Attendees will have the chance to engage with experts through a written Q&A session, and a recording of the event will be made available on the BioXcel Therapeutics website, ensuring broader dissemination and application of knowledge.
[object Object]
Preview
1.0
12-03Newsfilter
BioXcel Hosts Roundtable on Self-Administered Treatments for 77M Agitation Episodes
  • Event Focus: BioXcel Therapeutics is set to host a virtual roundtable on December 8, discussing the opportunities and advantages of self-administered treatments, which is expected to attract participation from medical experts, investors, and caregivers, thereby fostering discussions on new treatment paradigms.
  • Patient Demand: With an estimated 57 to 77 million agitation episodes related to bipolar disorder and schizophrenia occurring annually in the U.S., the urgent need for safe and effective self-treatment options in home settings is highlighted, potentially reshaping the future of patient care.
  • Expert Lineup: The roundtable will feature prominent medical experts, including Dr. Leslie Citrome from New York Medical College and Dr. Marc Milano from Newark Beth Israel Medical Center, sharing insights on future care models and facilitating cross-disciplinary knowledge exchange.
  • Technological Innovation: BioXcel Therapeutics leverages artificial intelligence to develop transformative medicines in neuroscience, showcasing the company's potential in drug re-innovation, which may provide new treatment options for patients.
[object Object]
Preview
1.0
10-13Newsfilter
BioXcel Therapeutics to Celebrate Major Neuroscience Achievement by Ringing Nasdaq Closing Bell on October 14

  • BioXcel Therapeutics Nasdaq Closing Bell Ceremony: BioXcel Therapeutics, Inc. will ring the Nasdaq Stock Market Closing Bell on October 14, 2025, celebrating its advancements in treating agitation associated with bipolar disorders and schizophrenia.

  • Commitment to Mental Health: CEO Vimal Mehta emphasized the company's dedication to improving the lives of patients and families affected by mental illness, highlighting the successful completion of the SERENITY At-Home trial and the goal of bringing IGALMI® to patients in their homes.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is BioXcel Therapeutics Inc (BTAI) stock price today?

The current price of BTAI is 2.09 USD — it has increased 9.42 % in the last trading day.

arrow icon

What is BioXcel Therapeutics Inc (BTAI)'s business?

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

arrow icon

What is the price predicton of BTAI Stock?

Wall Street analysts forecast BTAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BTAI is 10.67 USD with a low forecast of 4.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is BioXcel Therapeutics Inc (BTAI)'s revenue for the last quarter?

BioXcel Therapeutics Inc revenue for the last quarter amounts to 98.00K USD, decreased -54.21 % YoY.

arrow icon

What is BioXcel Therapeutics Inc (BTAI)'s earnings per share (EPS) for the last quarter?

BioXcel Therapeutics Inc. EPS for the last quarter amounts to -2.18 USD, decreased -57.67 % YoY.

arrow icon

What changes have occurred in the market's expectations for BioXcel Therapeutics Inc (BTAI)'s fundamentals?

The market is revising Downward the revenue expectations for BioXcel Therapeutics, Inc. (BTAI) for FY2025, with the revenue forecasts being adjusted by -24.68% over the past three months. During the same period, the stock price has changed by -44.85%.
arrow icon

How many employees does BioXcel Therapeutics Inc (BTAI). have?

BioXcel Therapeutics Inc (BTAI) has 37 emplpoyees as of December 05 2025.

arrow icon

What is BioXcel Therapeutics Inc (BTAI) market cap?

Today BTAI has the market capitalization of 45.71M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free